

## Supplemental Data

### Induction of Hepatitis by JNK-Mediated

#### Expression of TNF- $\alpha$

Madhumita Das, Guadalupe Sabio, Feng Jiang, Mercedes Rincón, Richard A. Flavell, and Roger J. Davis

### Supplemental Experimental Procedures

#### Flow cytometry.

Peripheral blood leukocytes and splenocytes ( $10^6$  cells) were incubated with anti-CD32/CD16 antibodies to block Fc receptors and then stained with PE-conjugated anti-CD4, APC-conjugated anti-CD8 plus FITC-conjugated anti-B220 antibody (Pharmingen) or with PE-conjugated anti-CD45.1 plus FITC-conjugated anti-CD45.2 (Pharmingen) in phosphate-buffered saline plus 2% serum. Flow cytometry was performed using a FACScan cytofluorometer (Becton Dickinson) and data were examined using FlowJo software.

#### Immunohistochemistry.

Livers were fixed in 4% paraformaldehyde, processed, and embedded in paraffin. Sections (5  $\mu$ m) were stained with hematoxylin and eosin (H&E) or by TUNEL assay using an *in situ* cell death kit (Roche). Hepatic damage detected in the stained liver sections was quantitated using ImagePro Plus software (Media Cybernetics).

#### Tissue culture.


Primary bone marrow-derived macrophages were prepared using methods described previously (Kim et al., 2004). Primary CD4<sup>+</sup> T cells from lymph nodes and spleen were isolated by positive selection using anti-CD4 MACS beads (Miltenyi) and cultured *in vitro*. Cytokine concentration in the culture medium was measured by multiplexed ELISA using a Luminex 200 instrument (Millipore).

#### Taqman<sup>®</sup> probes.


*Bax* (Mm 00432050 \_ m1), *cJun* (Mm 00495062 \_ s1), *cFos* (Mm 00487425 \_ m1), *Jnk1* (Mm0048915 \_ m1), *JunB* (Mm00492781 \_ s1), *JunD* (Mm 00495088 \_ s1), *Il22* (Mm00444241 \_ m1), *p53* (Mm00441964 \_ g1), *p21* (Mm 00432448 \_ m1), *Mdm2* (Mm00487656 \_ m1), *Puma* (Mm 00519268 \_ m1) and *Tnf $\alpha$*  (Mm\_00443258 \_ m1) probes were purchased from Applied Biosystems.

#### Statistical analysis.


Differences between groups were examined for statistical significance using the Student's test, analysis of variance (ANOVA) with the Fisher's test, or the log-rank test.




**Figure S1. JNK1-deficient and JNK2-deficient mice are not protected against ConA-induced hepatitis.** (A) Wild-type, *Jnk1*<sup>-/-</sup>, and *Jnk2*<sup>-/-</sup> mice were treated intravenously (8 hrs) with ConA or solvent (saline). Representative H&E-stained liver sections are presented. The amount of liver damage was quantitated (Figure S2A). (B,C) Serum transaminase activity (ALT and AST) in control and JNK-deficient mice after treatment (8 hrs) with ConA or solvent (saline) was measured (mean  $\pm$  SD; n = 6). No statistically significant differences between wild-type and JNK-deficient mice were detected. (D) The amount of serum cytokines (IL1, IL2, IL4, IL6, IL10, IL12, TNF $\alpha$ , and IFN $\gamma$ ) at 8 hrs. post-treatment with ConA was measured by ELISA (mean  $\pm$  SD; n = 4). Statistically significant differences between wild-type and JNK-deficient mice are indicated (\*, P < 0.05).



**Figure S2. Quantitation of hepatic damage caused by ConA and LPS.** Hepatic damage detected by staining liver sections with H&E was measured using ImagePro Plus (Media Cybernetics) software (mean % area  $\pm$  SD; n= 10). Statistically significant differences between wild-type and JNK-deficient mice are indicated (\*,  $P < 0.01$ ).



**Figure S3. JNK1-deficient and JNK2-deficient mice are protected against LPS-induced hepatitis.** (A) Wild-type, *Jnk1*<sup>-/-</sup>, and *Jnk2*<sup>-/-</sup> mice were treated intravenously (8 hrs) with LPS plus GalN or solvent (saline). Representative H&E-stained liver sections are presented. The amount of liver damage was quantitated (Figure S2B) (B) Serum transaminase activity (ALT and AST) in control and JNK-deficient mice after treatment (8 hrs) with LPS plus GalN or solvent (saline) was measured (mean  $\pm$  SD; n = 6). Statistically significant differences between wild-type and JNK-deficient mice are indicated (\*, P < 0.05). (C) The amount of serum cytokines (IFN $\gamma$ , TNF $\alpha$ , GM-CSF, IL6, IL10) post-treatment with LPS plus GalN was measured by ELISA (mean  $\pm$  SD; n = 6).



**Figure S4. JNK-deficiency causes defects in the expression of TNF $\alpha$  by T cells and macrophages.**


(A,B) Bone marrow-derived macrophages were isolated from wild-type, *Jnk1*<sup>-/-</sup>, and *Jnk2*<sup>-/-</sup> mice. The cells ( $1 \times 10^6$ ) were cultured in 1.0 ml medium and treated without and with 2.5  $\mu$ g of ConA or 1.0  $\mu$ g LPS. The concentration of TNF $\alpha$  in the culture medium was measured by ELISA at 4 hr (ConA) or 8 hr (LPS) post-treatment. (C,D) Bone marrow-derived macrophages were isolated from PolyIC-treated control mice (*Mx1-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1*<sup>fl</sup> *Jnk2*<sup>-/-</sup> *Cre*<sup>+</sup>) mice.

*Mx1-Cre*<sup>+</sup> mice. The concentration of TNF $\alpha$  in the culture medium was measured by ELISA at 24 hr (ConA) or 8 hr (LPS) post-treatment. (E) CD4 T cells were isolated from wild-type, *Jnk1*<sup>-/-</sup>, and *Jnk2*<sup>-/-</sup> mice. The cells ( $5 \times 10^5$ ) were cultured in 0.5 ml medium and treated without and with 1.25  $\mu$ g of ConA plus 0.5  $\mu$ g anti-CD28 (BD-Pharmingen). The concentration of TNF $\alpha$  in the culture medium was measured by ELISA at 48 hr post-treatment. (F) CD4 T cells were isolated from PolyIC-treated control mice (*Mx1-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1*<sup>fl/fl</sup> *Jnk2*<sup>-/-</sup> *Mx1-Cre*<sup>+</sup>) mice. The concentration of TNF $\alpha$  in the culture medium was measured by ELISA at 48 hr post-treatment with 1.25  $\mu$ g of ConA plus 0.5  $\mu$ g anti-CD28.

The data presented represent the mean  $\pm$  SD (n = 3). Statistically significant differences between control and JNK-deficient cells are indicated (\*, P < 0.05).


Studies of macrophages demonstrate that disruption of the *Jnk1* or *Jnk2* genes caused a significant decrease in ConA- and LPS- induced expression of TNF $\alpha$  (A,B). Similarly, compound deficiency of *Jnk1* plus *Jnk2* in macrophages also decreased TNF $\alpha$  expression in response to ConA and LPS (C,D). These data demonstrate that JNK1 and JNK2 play partially non-redundant roles in the response of macrophages to express TNF $\alpha$  when challenged with ConA or LPS *in vitro*. It is established that macrophages are an important target of LPS during the development of hepatitis (Dong et al., 2007). Thus, the non-redundant role of JNK1 and JNK2 in LPS-induced TNF $\alpha$  expression by macrophages may contribute to the observation that both *Jnk1*<sup>-/-</sup> mice and *Jnk2*<sup>-/-</sup> mice exhibit reduced LPS-induced hepatitis (Figure S3).

The sensitivity of *Jnk1*<sup>-/-</sup> mice and *Jnk2*<sup>-/-</sup> mice to ConA-induced hepatitis (Figure S1) may reflect a primary role of T cells, rather than macrophages, in the response to ConA during the development of hepatitis (Tiegs et al., 1992). We examined the response of isolated T cells to ConA *in vitro*. This analysis demonstrated that both *Jnk1*<sup>-/-</sup> T cells and *Jnk2*<sup>-/-</sup> T cells expressed reduced amounts of TNF $\alpha$  compared with wild-type T cells, but the difference was not statistically significant (E). In contrast, compound mutant *Jnk1*<sup>-/-</sup> *Jnk2*<sup>-/-</sup> T cells expressed significantly less TNF $\alpha$  than control T cells (F). These data indicate that JNK1 and JNK2 may have partially redundant roles in the response of T cells to express TNF $\alpha$  when challenged with ConA. This partial redundancy may contribute to the observation that both *Jnk1*<sup>-/-</sup> mice and *Jnk2*<sup>-/-</sup> mice exhibit only a modest reduction in ConA-induced hepatitis *in vivo* compared with wild-type mice (Figure S3).



**Figure S5. JNK-deficient mice exhibit reduced mortality in the ConA model of hepatitis.**


(A) PolyIC-treated control mice (*Mx1-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1*<sup>ff</sup> *Jnk2*<sup>-/-</sup> *Mx1-Cre*<sup>+</sup>) mice were treated with ConA. Kaplan-Meier analysis of the survival of groups of 12 mice per genotype demonstrated that the JNK-deficient mice exhibited reduced mortality compared with control mice (log-rank test;  $P < 0.005$ ). (B) Control mice (*Alb-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1*<sup>ff</sup> *Jnk2*<sup>-/-</sup> *Alb-Cre*<sup>+</sup>) mice were treated with ConA. Kaplan-Meier analysis of the survival of groups of 12 mice per genotype demonstrated that there was no statistically significant difference between the mortality of the control and JNK-deficient mice (log-rank test;  $P > 0.05$ ).



**Figure S6. JNK-deficient mice are protected against LPS-induced hepatitis.** (A) PolyIC-treated control mice (*Mx1-Cre<sup>+</sup>*) and JNK-deficient mice (*Jnk1<sup>f/f</sup> Jnk2<sup>-/-</sup> Mx1-Cre<sup>+</sup>*) were treated (8 hrs) with LPS plus GalN or solvent (saline). H&E-stained liver sections are presented. The amount of liver damage was quantitated (Figure S2D). (B) Serum transaminase activity (ALT and AST) in control and JNK-deficient mice after treatment (8 hrs) with LPS plus GalN or solvent (saline) was measured (mean  $\pm$  SD; n = 6). Statistically significant differences between




wild-type and JNK1/2-deficient mice are indicated (\*,  $P < 0.01$ ). (C) Liver extracts were prepared from control and JNK-deficient mice at 8 hrs post-treatment with LPS plus GalN or solvent (saline) and examined by immunoblot analysis using antibodies to cFLIP, and  $\alpha$ -Tubulin. The numbers on the left indicate the electrophoretic mobility of protein standards (kDa). (D) RNA was isolated from the liver of control and JNK-deficient mice after treatment (8 hrs) with LPS plus GalN or solvent (saline). The expression of *Gapdh*, *cJun*, *JunB*, *JunD*, *cFos*, and *Tnf $\alpha$*  mRNA was measured by quantitative RT-PCR (Taqman<sup>®</sup>) assays. The mRNA expression in each sample was normalized to the amount of *Gapdh* mRNA and presented as the mean  $\pm$  SD (n = 6). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (\*,  $P < 0.01$ ). (E) Serum TNF $\alpha$  was measured by ELISA after treatment (1 hr) with LPS plus GalN or saline (mean  $\pm$  SD; n = 6). Statistically significant differences between mice transplanted with control and JNK1/2-deficient bone marrow are indicated (\*,  $P < 0.01$ ).




**Figure S7. JNK-deficient mice exhibit reduced mortality in the LPS model of hepatitis.**

(A) PolyIC-treated control mice (*Mx1-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1<sup>ff</sup> Jnk2<sup>-/-</sup> Mx1-Cre*<sup>+</sup>) mice were treated with LPS plus GalN. Kaplan-Meier analysis of the survival of groups of 15 mice per genotype demonstrated that the JNK-deficient mice exhibited reduced mortality compared with control mice (log-rank test;  $P < 0.01$ ). (B) Control mice (*Alb-Cre*<sup>+</sup>) and JNK-deficient (*Jnk1<sup>ff</sup> Jnk2<sup>-/-</sup> Alb-Cre*<sup>+</sup>) mice were treated with TNF $\alpha$  plus GalN. Kaplan-Meier analysis of the survival of groups of 12 mice per genotype demonstrated that there was no statistically significant difference between the mortality of the control and JNK-deficient mice (log-rank test;  $P > 0.05$ ).



**Figure S8. Effect of hepatocyte-specific JNK-deficiency on serum cytokine expression.** (A) Control mice (*Alb-Cre*<sup>+</sup>) and mice with hepatocyte-specific JNK-deficiency (*Jnk1*<sup>fl/fl</sup> *Jnk2*<sup>-/-</sup> *Alb-Cre*<sup>+</sup>) were treated intravenously with LPS plus GalN. The amount of serum cytokines (TNF $\alpha$ , IL6, and IL10) post-treatment with LPS plus GalN was measured by ELISA (mean  $\pm$  SD; n = 7). (B) The amount of total and phospho- JNK1/2, cJun, ERK1/2, p38 MAPK, and AKT in liver extracts at 8 hrs post-treatment of mice with LPS plus GalN or saline was measured by ELISA (mean  $\pm$  SD; n = 5).

Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (\*, P < 0.05).



**Figure S9. Effect of JNK-deficiency on the expression of IL22.** Control mice ( $Mxl-Cre^+$ ) and JNK-deficient ( $Jnk1^{fl/fl} Jnk2^{-/-} Mxl-Cre^+$ ) were treated without and with ConA. The expression of *Il22* mRNA in the liver at 1 hr post-injection was examined by quantitative RT-PCR (Taqman<sup>®</sup>) assays. The mRNA expression in each sample was normalized to the amount of *Gapdh* mRNA and presented as the mean  $\pm$  SD (n = 6). No statistically significant differences between wild-type and JNK-deficient mice were detected (P > 0.05).

## Supplemental References

- Das, M., Jiang, F., Sluss, H. K., Zhang, C., Shokat, K. M., Flavell, R. A., and Davis, R. J. (2007). Suppression of p53-dependent senescence by the JNK signal transduction pathway. *Proc Natl Acad Sci U S A* *104*, 15759-15764.
- Dong, C., Yang, D. D., Wysk, M., Whitmarsh, A. J., Davis, R. J., and Flavell, R. A. (1998). Defective T cell differentiation in the absence of Jnk1. *Science* *282*, 2092-2095.
- Dong, Z., Wei, H., Sun, R., and Tian, Z. (2007). The roles of innate immune cells in liver injury and regeneration. *Cell Mol Immunol* *4*, 241-252.
- Kim, L., Butcher, B. A., and Denkers, E. Y. (2004). *Toxoplasma gondii* interferes with lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms distinct from endotoxin tolerance. *J Immunol* *172*, 3003-3010.
- Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible gene targeting in mice. *Science* *269*, 1427-1429.
- Mikkola, H. K., Klintman, J., Yang, H., Hock, H., Schlaeger, T. M., Fujiwara, Y., and Orkin, S. H. (2003). Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. *Nature* *421*, 547-551.
- Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., and Magnuson, M. A. (1999). Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem* *274*, 305-315.
- Tiegs, G., Hentschel, J., and Wendel, A. (1992). A T cell-dependent experimental liver injury in mice inducible by concanavalin A. *J Clin Invest* *90*, 196-203.
- Yang, D. D., Conze, D., Whitmarsh, A. J., Barrett, T., Davis, R. J., Rincon, M., and Flavell, R. A. (1998). Differentiation of CD4<sup>+</sup> T cells to Th1 cells requires MAP kinase JNK2. *Immunity* *9*, 575-585.